A Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Therapeutic Plasma Exchange (Plasmapheresis) in Participants With Duchenne Muscular Dystrophy (DMD) and Pre-existing Antibodies to AAVrh74

Name: A Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Therapeutic Plasma Exchange (Plasmapheresis) in Participants With Duchenne Muscular Dystrophy (DMD) and Pre-existing Antibodies to AAVrh74
Published: 2024
License: Public Domain

Sarepta Therapeutics, Inc. · 2024

ClinicalTrials.gov · Datasets · License: Public Domain · 2024

Open Source ↗

duchenne-muscular-dystrophy pediatric

duchenne muscular dystrophy, gene-delivery, dmd, ambulatory, pediatric, duchenne, seropositive, pre-existing antibodies, aavrh74 antibody, plasmapheresis, titer, seropositivity

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 870870
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.